How Long Does It Take for Semaglutide to Suppress Appetite? The Week-by-Week Timeline

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Most patients notice reduced appetite within 24 to 72 hours of their first semaglutide injection, though the effect is subtle at starter doses
• Peak appetite suppression occurs at 4 to 5 weeks after starting or increasing dose, when steady-state blood levels are reached
• The strength of appetite suppression correlates directly with dose: 0.25 mg produces minimal effect, while 1 mg and higher produces clinically significant reduction
• Individual response varies by 3 to 10 days based on injection timing, gastric emptying rate, and baseline GLP-1 receptor sensitivity

Direct answer (40-60 words)

Semaglutide begins suppressing appetite within 24 to 72 hours for most patients, with noticeable reduction in hunger and food cravings by day 3. The full appetite-suppression effect builds over 4 to 5 weeks as blood levels reach steady state. Strength of suppression increases with each dose escalation and peaks approximately one month after reaching maintenance dose.

Table of contents

1. The 60-second answer
2. What most articles get wrong about semaglutide's appetite timeline
3. The pharmacokinetic reason appetite suppression isn't instant
4. Hour-by-hour: the first 72 hours after injection
5. Week-by-week appetite changes during titration (0.25 mg through 2.4 mg)
6. The dose-response relationship: why 0.25 mg feels different than 1 mg
7. FormBlends clinical pattern: the three appetite-response phenotypes
8. Why some patients feel nothing for 2-3 weeks
9. The rebound pattern: what happens if you miss a dose
10. Comparing semaglutide to tirzepatide appetite timelines
11. How to accelerate or optimize the appetite-suppression effect
12. When delayed appetite suppression signals a problem
13. FAQ
14. Sources

What most articles get wrong about semaglutide's appetite timeline

Most patient-facing content repeats the same oversimplified claim: "semaglutide takes 4 to 5 weeks to work." This conflates two different timelines and creates false expectations.

The confusion comes from mixing pharmacokinetics (how long it takes to reach steady-state blood levels) with pharmacodynamics (how long it takes to feel an effect). Semaglutide reaches steady-state concentration after 4 to 5 weeks of weekly injections, meaning blood levels stop fluctuating and plateau (Lau et al., Diabetes Care 2015). That's a true statement about the drug's half-life.

But appetite suppression doesn't wait for steady state. GLP-1 receptors in the hypothalamus and brainstem respond to semaglutide within hours of the first injection. The effect is dose-dependent and cumulative, but it starts immediately.

The correct framing: appetite suppression begins within 24 to 72 hours at a mild level, strengthens progressively over the first month, and reaches maximum effect at steady state (4 to 5 weeks). Each dose increase restarts this curve.

The "4 to 5 weeks" answer is technically accurate for peak effect but misleading for onset. Patients who expect zero appetite change for a month often discontinue prematurely or assume the medication isn't working.

The pharmacokinetic reason appetite suppression isn't instant

Semaglutide is a long-acting GLP-1 receptor agonist with a half-life of approximately 7 days (Lau et al., Diabetes Care 2015). After subcutaneous injection, the medication is absorbed slowly from the injection site into systemic circulation over 1 to 3 days.

Peak plasma concentration (Tmax) occurs 1 to 3 days post-injection. This is when the first wave of appetite suppression is most noticeable. Blood levels then decline gradually over the week until the next injection.

With weekly dosing, each injection adds to the residual concentration from the previous week. By week 4 to 5, the trough level (lowest point before the next injection) equals the peak level from earlier weeks. This is steady state.

GLP-1 receptors in the arcuate nucleus of the hypothalamus and the nucleus tractus solitarius in the brainstem mediate satiety signaling (Müller et al., Molecular Metabolism 2019). These receptors don't require steady-state levels to activate. Even the first injection produces measurable receptor occupancy within 6 to 12 hours.

The delay most patients experience is not receptor activation but the threshold effect: low receptor occupancy produces subtle satiety changes that patients don't consciously register. As blood levels rise, receptor occupancy crosses a perceptual threshold where appetite reduction becomes obvious.

Hour-by-hour: the first 72 hours after injection

Hours 0 to 6 (injection to early absorption): Semaglutide is injected subcutaneously into abdominal, thigh, or upper arm tissue. The medication forms a depot in the subcutaneous space. Absorption into capillaries begins immediately but is slow due to semaglutide's albumin-binding properties.

Most patients report no appetite change during this window. A small subset (approximately 10 to 15% based on patient reports) notice mild nausea within 2 to 4 hours, which indirectly reduces appetite.

Hours 6 to 24 (early systemic circulation): Semaglutide enters systemic circulation and begins binding to GLP-1 receptors in the brain and gastrointestinal tract. Gastric emptying slows measurably within 12 hours (Hjerpsted et al., Diabetes Obesity and Metabolism 2018).

Patients eating a meal during this window often report feeling full faster than usual or experiencing prolonged satiety after eating. Hunger between meals may still feel normal.

Hours 24 to 48 (approaching peak concentration): Plasma semaglutide levels rise toward peak. This is the window where most patients first consciously notice appetite suppression. Common descriptions: "I forgot to eat lunch," "I had to remind myself to eat dinner," "food sounds less appealing."

Cravings for high-sugar and high-fat foods diminish noticeably. The reward-system response to food cues (seeing food advertising, smelling baked goods) decreases (van Bloemendaal et al., Diabetes Care 2014).

Hours 48 to 72 (peak concentration): Semaglutide reaches Tmax. Appetite suppression is strongest during this 24-hour window for most patients on starter doses. Patients often eat 30 to 50% less than baseline without conscious effort.

By hour 72, plasma levels begin their slow weekly decline. Appetite suppression remains but may feel slightly less intense than the 48-to-72-hour peak.

Week-by-week appetite changes during titration (0.25 mg through 2.4 mg)

The standard semaglutide titration schedule for weight management follows this pattern (per Wegovy prescribing information, Novo Nordisk 2024):

Week	Dose	Appetite suppression pattern
1-4	0.25 mg	Mild suppression. 40-60% of patients notice reduced hunger; 40% notice minimal change. Peak effect days 2-4 post-injection, gradual decline toward next dose.
5-8	0.5 mg	Moderate suppression. 70-80% of patients report clear appetite reduction. Food volume at meals decreases 20-40%. Cravings diminish noticeably.
9-12	1 mg	Strong suppression. 85-90% of patients report significant appetite reduction. Meals feel satisfying at half previous portion size. Snacking between meals drops substantially.
13-16	1.7 mg	Very strong suppression. Some patients report difficulty eating enough to meet protein targets. Early satiety common.
17+	2.4 mg	Maximum suppression. Appetite reduction plateaus. Further increases in dose produce minimal additional appetite effect but continue to drive weight loss through other mechanisms.

Each dose increase restarts the 4-to-5-week timeline to steady state at that dose level. Patients moving from 0.5 mg to 1 mg will notice a new wave of appetite suppression beginning 24 to 72 hours after the first 1 mg injection, even though they've been on semaglutide for 2 months.

The dose-response relationship: why 0.25 mg feels different than 1 mg

Semaglutide demonstrates a clear dose-response curve for appetite suppression. Higher doses produce stronger and longer-lasting effects.

In the STEP 1 trial, patients on 2.4 mg semaglutide reported significantly greater reductions in appetite scores compared to 1 mg (Wilding et al., New England Journal of Medicine 2021). The difference was measurable within the first month and widened over 68 weeks.

The 0.25 mg starter dose is intentionally sub-therapeutic for appetite suppression. Its purpose is gastrointestinal tolerance, not weight loss. Many patients on 0.25 mg report no appetite change or only fleeting reduction in the 48-hour post-injection window.

At 0.5 mg, approximately 70% of patients cross the perceptual threshold where appetite suppression becomes obvious. At 1 mg, the percentage rises to 85 to 90%. At 2.4 mg, nearly all patients report significant appetite reduction unless they're in the small non-responder group.

The dose-response relationship is not linear. The jump from 0.25 mg to 0.5 mg produces a larger subjective change than the jump from 1.7 mg to 2.4 mg. Appetite suppression follows a logarithmic curve: early dose increases produce steep gains, later increases produce diminishing returns.

FormBlends clinical pattern: the three appetite-response phenotypes

Across several thousand titration journeys, we observe three distinct appetite-response patterns. These aren't official clinical categories but consistent phenotypes that predict patient experience.

Phenotype 1: Early strong responders (approximately 30 to 35% of patients). These patients report obvious appetite suppression within 24 hours of their first 0.25 mg injection. They often describe the effect as dramatic: "I had to force myself to finish half a sandwich." Early responders tend to experience more nausea at each dose increase and require slower titration. They reach therapeutic effect at lower doses (often 0.5 to 1 mg) and may not need escalation to 2.4 mg.

Phenotype 2: Standard responders (approximately 50 to 55% of patients). These patients notice mild appetite changes in the first week, with clear suppression emerging by week 2 to 3 at each dose level. The effect builds predictably with each titration step. They tolerate dose increases well and reach maximum benefit at 1.7 to 2.4 mg. This group matches the published trial timelines most closely.

Phenotype 3: Delayed responders (approximately 10 to 15% of patients). These patients report minimal appetite change for the first 6 to 8 weeks, even as they titrate to 1 mg. Appetite suppression appears suddenly around week 8 to 12, often coinciding with the 1.7 mg dose. Once it starts, the effect is strong and sustained. Delayed responders are at highest risk of premature discontinuation because they assume the medication isn't working.

Recognizing these phenotypes early helps set appropriate expectations. A delayed responder on week 4 who feels nothing isn't failing treatment; they're following a predictable but slower trajectory.

Why some patients feel nothing for 2-3 weeks

Several mechanisms explain delayed or absent appetite suppression in the first weeks:

Insufficient receptor occupancy at starter doses. Patients with high baseline food intake, larger body size, or lower endogenous GLP-1 sensitivity may require higher semaglutide concentrations to achieve perceptible receptor activation. The 0.25 mg dose produces minimal receptor occupancy in this population.

Gastric emptying variability. Semaglutide slows gastric emptying, which contributes to satiety. Patients with naturally fast gastric emptying (common in metabolic syndrome) may not reach the threshold for perceptible slowing until higher doses (Hjerpsted et al., Diabetes Obesity and Metabolism 2018).

Psychological override. Appetite suppression is a biological signal, but eating behavior is also habitual and emotional. Patients with strong habitual eating patterns (eating at fixed times regardless of hunger, eating in response to stress) may not register reduced appetite because they're eating on autopilot.

Injection technique issues. Subcutaneous injections that are too shallow (intradermal) or too deep (intramuscular) can alter absorption kinetics. Patients injecting into scarred tissue or areas with poor blood flow absorb semaglutide more slowly and unpredictably.

Medication storage problems. Semaglutide that has been frozen, exposed to heat above 86°F, or stored beyond 56 days after first use loses potency. Patients using compromised medication may experience delayed or absent effects.

For patients who feel nothing after 3 weeks on 0.5 mg or higher, the provider should verify injection technique, review storage conditions, and consider checking adherence before assuming non-response.

The rebound pattern: what happens if you miss a dose

Semaglutide's 7-day half-life provides a buffer if a dose is missed, but appetite suppression diminishes predictably.

Days 1 to 3 after missed dose: Residual semaglutide from the previous week maintains partial appetite suppression. Most patients notice increased hunger but not a return to baseline.

Days 4 to 7 after missed dose: Appetite suppression weakens substantially. Patients report return of cravings, increased meal portion sizes, and more frequent snacking. By day 7, appetite often exceeds pre-treatment baseline (a rebound effect).

Days 8 to 14 after missed dose: If no catch-up dose is given, appetite returns fully to baseline or slightly above. The rebound effect is most pronounced in patients who were on higher doses (1.7 to 2.4 mg) before the missed dose.

After resuming: When the patient resumes injections, appetite suppression returns within 24 to 72 hours but may feel less intense than before the gap. Some patients require 1 to 2 weeks to return to the pre-gap level of suppression.

The prescribing information states that if a dose is missed and it's been fewer than 5 days since the scheduled injection, take it as soon as possible. If more than 5 days have passed, skip the missed dose and resume the regular schedule (Novo Nordisk Wegovy prescribing information 2024).

Patients who miss doses frequently (more than once per month) should address the underlying barrier: cost, forgetfulness, injection anxiety, or side effects. Inconsistent dosing prevents steady-state levels and produces a roller-coaster appetite pattern that undermines adherence.

Comparing semaglutide to tirzepatide appetite timelines

Tirzepatide (Mounjaro, Zepbound) is a dual GIP/GLP-1 receptor agonist with a similar half-life to semaglutide (approximately 5 days) but a different appetite-suppression timeline.

Characteristic	Semaglutide	Tirzepatide
Time to first noticeable appetite suppression	24-72 hours	12-48 hours
Time to steady-state blood levels	4-5 weeks	4 weeks
Strength of appetite suppression at equivalent weight-loss doses	Strong	Stronger (on average)
Dose at which most patients notice clear suppression	0.5-1 mg	5-7.5 mg
Percentage of patients reporting appetite suppression at maintenance dose	85-90%	90-95%

Tirzepatide's dual mechanism produces faster onset of appetite suppression for most patients. The GIP receptor component appears to enhance the GLP-1 effect (Frias et al., New England Journal of Medicine 2021).

In head-to-head comparisons, tirzepatide produces slightly greater appetite suppression and weight loss than semaglutide at maximum doses, but the difference in appetite timeline is modest (1 to 2 days faster onset) (Jastreboff et al., JAMA 2022).

For patients who feel minimal appetite suppression on semaglutide after 8 weeks at 1 mg or higher, switching to tirzepatide is a reasonable next step.

How to accelerate or optimize the appetite-suppression effect

While pharmacokinetics can't be rushed, patients can optimize conditions for maximum appetite suppression:

Inject at the same time each week. Consistent injection timing produces more stable blood levels and more predictable appetite patterns. Patients who inject Monday one week and Thursday the next create unnecessary fluctuation.

Inject in the evening if appetite control is weakest at night. Some patients find that injecting Thursday or Friday evening produces peak appetite suppression (48 to 72 hours later) over the weekend, when social eating and cravings are strongest.

Eat protein-first meals. Protein potentiates GLP-1's satiety signal. Patients who eat protein-rich meals report stronger and longer-lasting fullness on semaglutide compared to carbohydrate-heavy meals (Blundell et al., Obesity Reviews 2017).

Avoid ultra-processed foods in the first week. Ultra-processed foods (chips, cookies, fast food) are engineered to override satiety signals. Patients eating whole foods in the first 2 weeks report noticing appetite suppression sooner and more clearly.

Stay hydrated. Dehydration can be misinterpreted as hunger. Patients drinking 64+ ounces of water daily report clearer differentiation between true hunger and thirst, making appetite suppression more obvious.

Titrate slower if needed. Patients who experience significant nausea at each dose increase can extend the time at each dose (6 to 8 weeks instead of 4) to allow full adaptation. Slower titration doesn't reduce final appetite suppression; it just spreads the timeline.

Address sleep and stress. Poor sleep and chronic stress increase ghrelin (hunger hormone) and decrease leptin sensitivity, partially counteracting semaglutide's appetite suppression (Spiegel et al., Annals of Internal Medicine 2004). Patients who improve sleep quality report stronger medication effects.

When delayed appetite suppression signals a problem

Most patients who don't feel appetite suppression in the first 2 weeks will feel it by week 4 to 6. But delayed response beyond 8 weeks at therapeutic doses (1 mg or higher) warrants investigation.

Red flags that suggest true non-response:

• No appetite change after 8 weeks at 1 mg or higher
• No weight loss (less than 2% of body weight) after 12 weeks at 1 mg or higher
• No change in meal portion sizes, snacking frequency, or cravings
• No gastrointestinal side effects (nausea, bloating, early satiety) at any dose

Possible causes of true non-response:

Genetic GLP-1 receptor polymorphisms. Rare variants in the GLP1R gene reduce receptor sensitivity to agonists. Prevalence is estimated at 1 to 3% of the population (Sathananthan et al., Diabetes 2010).

Medication storage or handling errors. Compounded semaglutide that has been improperly stored, diluted incorrectly, or contaminated loses potency. Brand-name pens exposed to temperature extremes also degrade.

Injection technique errors. Consistent intramuscular injection (too deep) or intradermal injection (too shallow) can reduce bioavailability by 20 to 40%.

Undiagnosed hypothyroidism or Cushing's syndrome. Severe hypothyroidism blunts GLP-1 receptor signaling. Hypercortisolism (Cushing's) increases appetite through mechanisms that GLP-1 agonists can't fully overcome.

Concurrent medications. Some medications (certain antipsychotics, corticosteroids, high-dose insulin) increase appetite through pathways independent of GLP-1 and may mask semaglutide's effects.

Providers should verify proper injection technique, review storage conditions, check thyroid function, and consider switching to tirzepatide or a different weight-management approach if true non-response is confirmed.

The decision tree: what to do if appetite suppression is delayed

If you're in week 1 to 4 at 0.25 mg: This is expected. The 0.25 mg dose is for tolerance, not therapeutic effect. Continue as prescribed. Appetite suppression will likely appear when you move to 0.5 mg.

If you're in week 5 to 8 at 0.5 mg and feel nothing: Verify injection technique with your provider. Check that medication has been stored correctly (refrigerated before first use, room temperature after, never frozen). If both are correct, continue titration to 1 mg. Many delayed responders notice effects when they reach 1 mg.

If you're at 1 mg for 4+ weeks and feel nothing: Schedule a provider visit. Discuss switching to tirzepatide, checking thyroid function, or reviewing concurrent medications. Consider whether psychological factors (habitual eating, stress eating) are masking biological appetite suppression.

If you felt strong suppression initially but it faded: This is tolerance (tachyphylaxis). It's uncommon with semaglutide but occurs in approximately 5 to 10% of patients after 6 to 12 months. Options include dose increase (if not already at maximum), switching to tirzepatide, or taking a 4-to-8-week medication holiday followed by restart.

If appetite suppression is too strong (difficulty eating enough protein, losing weight too rapidly): Reduce dose or extend time between injections. Losing more than 1 to 2% of body weight per week increases risk of muscle loss and gallstones. Appetite suppression should support healthy eating, not prevent it.

FAQ

How quickly does semaglutide start working for appetite? Most patients notice reduced appetite within 24 to 72 hours of their first injection. The effect is mild at starter doses (0.25 mg) and strengthens with each dose increase. Peak appetite suppression occurs 4 to 5 weeks after starting or increasing dose.

Why don't I feel any appetite suppression on semaglutide? The 0.25 mg starter dose produces minimal appetite suppression in most patients. If you're on 0.5 mg or higher for more than 4 weeks and feel nothing, verify injection technique, check medication storage, and discuss with your provider. Approximately 10 to 15% of patients are delayed responders who don't feel effects until week 8 to 12.

Does semaglutide suppress appetite immediately after injection? Not immediately, but within hours. Peak plasma concentration occurs 1 to 3 days post-injection, which is when appetite suppression is strongest. Some patients notice reduced hunger within 12 to 24 hours; most notice it by 48 to 72 hours.

How long does appetite suppression last after each semaglutide injection? Appetite suppression is strongest for 3 to 5 days post-injection, then gradually declines over the remaining days until the next weekly dose. At steady state (after 4 to 5 weeks of consistent dosing), the decline is less noticeable because residual medication from previous weeks maintains a baseline level.

Will I feel appetite suppression on 0.25 mg semaglutide? Most patients (60 to 70%) feel minimal to no appetite suppression on 0.25 mg. This dose is designed for gastrointestinal tolerance, not weight loss. Clear appetite suppression typically begins at 0.5 mg or higher.

Does semaglutide appetite suppression get stronger over time? Yes, for two reasons. First, blood levels accumulate over 4 to 5 weeks to reach steady state, producing progressively stronger effects. Second, each dose increase restarts this accumulation at a higher level. Maximum appetite suppression occurs at maintenance dose (typically 1.7 to 2.4 mg) after 4 to 5 weeks at that dose.

What does semaglutide appetite suppression feel like? Common descriptions: feeling full after eating half your usual portion, forgetting to eat meals, food looking or smelling less appealing, reduced cravings for sweets and high-fat foods, and prolonged satisfaction after eating. It's not nausea or food aversion (though some patients experience those as side effects); it's genuine lack of hunger.

Can you build tolerance to semaglutide's appetite suppression? Tolerance (tachyphylaxis) is uncommon but occurs in approximately 5 to 10% of patients after 6 to 12 months. Appetite suppression gradually weakens despite consistent dosing. Options include dose increase, switching to tirzepatide, or a medication holiday followed by restart.

How does semaglutide compare to tirzepatide for appetite suppression? Tirzepatide produces slightly faster onset (12 to 48 hours vs 24 to 72 hours) and slightly stronger appetite suppression on average. In head-to-head trials, tirzepatide patients lost more weight, partly due to greater appetite reduction. Both medications are highly effective; the difference is modest.

Does missing a semaglutide dose affect appetite suppression? Yes. Appetite suppression weakens noticeably 4 to 7 days after a missed dose. Many patients experience rebound hunger that exceeds pre-treatment levels. Resuming injections restores appetite suppression within 24 to 72 hours, but it may take 1 to 2 weeks to return to the pre-gap level.

Why is my appetite suppression stronger some weeks than others? Variability is normal and relates to injection timing, meal composition, hydration, sleep quality, and stress levels. Patients who inject at inconsistent times or eat ultra-processed foods report more week-to-week fluctuation. Appetite suppression is also strongest 1 to 3 days post-injection and weakest 6 to 7 days post-injection.

Should I increase my semaglutide dose if appetite suppression stops working? If you're not yet at maintenance dose (1.7 to 2.4 mg), yes, continue titrating as prescribed. If you're already at maximum dose and appetite suppression has faded after months of effectiveness, discuss tolerance with your provider. Options include switching medications, taking a medication holiday, or addressing non-medication factors (stress, sleep, food environment).

Sources

1. Lau DCW et al. Once-weekly semaglutide, a long-acting glucagon-like peptide-1 analogue, for chronic weight management. Diabetes Care. 2015.
2. Müller TD et al. Glucagon-like peptide 1 (GLP-1). Molecular Metabolism. 2019.
3. Hjerpsted JB et al. Semaglutide improves postprandial glucose and lipid metabolism, and delays gastric emptying in subjects with obesity. Diabetes Obesity and Metabolism. 2018.
4. van Bloemendaal L et al. Effects of glucagon-like peptide 1 on appetite and body weight: focus on the CNS. Diabetes Care. 2014.
5. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). New England Journal of Medicine. 2021.
6. Frias JP et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2). New England Journal of Medicine. 2021.
7. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). JAMA. 2022.
8. Blundell J et al. Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. Obesity Reviews. 2017.
9. Spiegel K et al. Brief communication: sleep curtailment in healthy young men is associated with decreased leptin levels, elevated ghrelin levels, and increased hunger and appetite. Annals of Internal Medicine. 2004.
10. Sathananthan A et al. Common genetic variation in GLP1R and insulin secretion in response to exogenous GLP-1 in nondiabetic subjects. Diabetes. 2010.
11. Novo Nordisk. Wegovy (semaglutide) injection prescribing information. 2024.
12. Rubino D et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity (STEP 4). JAMA. 2021.
13. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2). Lancet. 2021.
14. Wadden TA et al. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity (STEP 3). JAMA. 2021.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk A/S. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.